HR and breast cancer: However, direct comparisons between the three inhibitors combined with ET and a single CDK4/6 inhibitor or ET, as well as between the three inhibitors combined with ET, are still lacking, which hinders the selection of clinical drugs for HR+/HER2-breast cancer patients.